300485 赛升药业
已收盘 01-13 15:00:00
资讯
新帖
简况
1月13日赛升药业现1笔折价12.01%的大宗交易 合计成交877.4万元
证券之星 · 01-13 17:33
1月13日赛升药业现1笔折价12.01%的大宗交易 合计成交877.4万元
股市必读：赛升药业(300485)股东户数3.36万户，较上期减少2.16%
证券之星 · 01-09
股市必读：赛升药业(300485)股东户数3.36万户，较上期减少2.16%
赛升药业（300485）披露向子公司君元药业提供财务资助展期，12月29日股价下跌0.28%
证券之星 · 2025-12-29
赛升药业（300485）披露向子公司君元药业提供财务资助展期，12月29日股价下跌0.28%
赛升药业：截至2025年12月19日股东户数为34363
证券之星 · 2025-12-24
赛升药业：截至2025年12月19日股东户数为34363
赛升药业：截至2025年12月10日股东户数为35036
证券之星 · 2025-12-15
赛升药业：截至2025年12月10日股东户数为35036
赛升药业（300485）披露子公司收到药品注册上市许可申请受理通知书，12月4日股价下跌0.17%
证券之星 · 2025-12-04
赛升药业（300485）披露子公司收到药品注册上市许可申请受理通知书，12月4日股价下跌0.17%
赛升药业(300485.SZ)：达格列净二甲双胍缓释片药品注册上市许可申请获受理
智通财经 · 2025-12-04
赛升药业(300485.SZ)：达格列净二甲双胍缓释片药品注册上市许可申请获受理
赛升药业：11月18日高管马丽减持股份合计6.3万股
证券之星 · 2025-11-19
赛升药业：11月18日高管马丽减持股份合计6.3万股
股市必读：赛升药业(300485)股东户数3.56万户，较上期减少4.03%
证券之星 · 2025-11-18
股市必读：赛升药业(300485)股东户数3.56万户，较上期减少4.03%
股市必读：赛升药业（300485）11月7日董秘有最新回复
证券之星 · 2025-11-10
股市必读：赛升药业（300485）11月7日董秘有最新回复
赛升药业最新公告：取得换发《药品生产许可证》
证券之星 · 2025-11-07
赛升药业最新公告：取得换发《药品生产许可证》
赛升药业：公司现任董事长为马骉先生
证券之星 · 2025-11-07
赛升药业：公司现任董事长为马骉先生
赛升药业：截至2025年10月20日股东户数为37145
证券之星 · 2025-10-30
赛升药业：截至2025年10月20日股东户数为37145
赛升药业（300485）2025年三季报简析：净利润同比增长152.81%
证券之星 · 2025-10-25
赛升药业（300485）2025年三季报简析：净利润同比增长152.81%
赛升药业最新公告：第三季度净利润同比下降41.41%
证券之星 · 2025-10-23
赛升药业最新公告：第三季度净利润同比下降41.41%
赛升药业(300485)9月30日股东户数3.34万户，较上期减少1.82%
证券之星 · 2025-10-13
赛升药业(300485)9月30日股东户数3.34万户，较上期减少1.82%
赛升药业(300485)9月19日股东户数3.4万户，较上期减少0.79%
证券之星 · 2025-09-25
赛升药业(300485)9月19日股东户数3.4万户，较上期减少0.79%
股市必读：赛升药业（300485）9月19日董秘有最新回复
证券之星 · 2025-09-22
股市必读：赛升药业（300485）9月19日董秘有最新回复
赛升药业(300485.SZ)股东马丽和刘淑芹拟合计减持不超2%股份
智通财经 · 2025-09-19
赛升药业(300485.SZ)股东马丽和刘淑芹拟合计减持不超2%股份
赛升药业：布局生命科学大健康产业
证券之星 · 2025-09-19
赛升药业：布局生命科学大健康产业
加载更多
公司概况
公司名称：
北京赛升药业股份有限公司
所属行业：
医药制造业
上市日期：
2015-06-26
主营业务：
北京赛升药业股份有限公司的主营业务是注射针剂的研发、生产及销售。公司的主要产品是免疫系统用药、神经系统用药、心脑血管用药。赛盈®纤溶酶注射液被评选为2023年年度生化生物企业优秀品牌，赛典®单唾液酸四己糖神经节苷脂钠注射液被评为2024年度生化、生物药品优秀品牌。
发行价格：
38.46
{"stockData":{"symbol":"300485","market":"SZ","secType":"STK","nameCN":"赛升药业","latestPrice":12.16,"timestamp":1768287816000,"preClose":11.43,"halted":0,"volume":33723317,"delay":0,"changeRate":0.0639,"floatShares":274000000,"shares":482000000,"eps":0.1686,"marketStatus":"已收盘","change":0.73,"latestTime":"01-13 15:00:00","open":11.42,"high":12.6,"low":11.42,"amount":410000000,"amplitude":0.1032,"askPrice":12.16,"askSize":85,"bidPrice":12.15,"bidSize":208,"shortable":0,"etf":0,"ttmEps":0.1686,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768354200000},"marketStatusCode":5,"adr":0,"adjPreClose":11.43,"symbolType":"stock","openAndCloseTimeList":[[1768267800000,1768275000000],[1768280400000,1768287600000]],"highLimit":12.57,"lowLimit":10.29,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":481666400,"isCdr":false,"pbRate":1.62,"roa":"--","peRate":72.123369,"roe":"1.53%","epsLYR":-0.14,"committee":-0.327668,"marketValue":5857000000,"turnoverRate":0.1232,"status":0,"floatMarketCap":3330000000},"requestUrl":"/m/hq/s/300485","defaultTab":"news","newsList":[{"id":"2603502378","title":"1月13日赛升药业现1笔折价12.01%的大宗交易 合计成交877.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603502378","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603502378?lang=zh_cn&edition=full","pubTime":"2026-01-13 17:33","pubTimestamp":1768296797,"startTime":"0","endTime":"0","summary":"证券之星消息，1月13日赛升药业发生大宗交易，交易数据如下：大宗交易成交价格10.7元，相对当日收盘价折价12.01%，成交82万股，成交金额877.4万元，买方营业部为中国银河证券股份有限公司北京建国路证券营业部，卖方营业部为兴业证券股份有限公司上海自由贸易试验区分公司。近三个月该股共发生1笔大宗交易，合计成交8200.0手，折价成交1笔。截至2026年1月13日收盘，赛升药业报收于12.16元，上涨6.39%，换手率12.32%，成交量33.72万手，成交额4.1亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300029380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300485","BK0028","BK0012"],"gpt_icon":0},{"id":"2602394550","title":"股市必读：赛升药业(300485)股东户数3.36万户，较上期减少2.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602394550","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602394550?lang=zh_cn&edition=full","pubTime":"2026-01-09 01:55","pubTimestamp":1767894913,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘，赛升药业报收于11.25元，上涨1.26%，换手率2.79%，成交量7.65万手，成交额8634.3万元。来自股本股东变化：截至2025年12月31日股东户数环比下降2.16%，户均持股上升至1.43万股，筹码集中度有所提高。股本股东变化股东户数变动近日赛升药业披露，截至2025年12月31日公司股东户数为3.36万户，较12月19日减少742.0户，减幅为2.16%。户均持股数量由上期的1.4万股增加至1.43万股，户均持股市值为15.16万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900001189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0012","BK0028","BK0239","300485"],"gpt_icon":0},{"id":"2595736431","title":"赛升药业（300485）披露向子公司君元药业提供财务资助展期，12月29日股价下跌0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595736431","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595736431?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:56","pubTimestamp":1767020179,"startTime":"0","endTime":"0","summary":"截至2025年12月29日收盘，赛升药业报收于10.7元，较前一交易日下跌0.28%，最新总市值为51.54亿元。近日，赛升药业发布公告称，公司拟对子公司沈阳君元药业有限公司提供的不超过3,000万元财务资助进行展期，借款期限延长至2028年12月28日，年利率3%。君元药业为公司控股子公司，公司能有效控制其业务与资金管理，风险可控。截至公告日，公司对外提供财务资助总额为5,000万元，无逾期情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900038439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","BK0239","300485","BK0012"],"gpt_icon":0},{"id":"2593442513","title":"赛升药业：截至2025年12月19日股东户数为34363","url":"https://stock-news.laohu8.com/highlight/detail?id=2593442513","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593442513?lang=zh_cn&edition=full","pubTime":"2025-12-24 09:06","pubTimestamp":1766538371,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)12月23日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好！请问公司截至12月20日公司的股东人数是多少？谢谢赛升药业回复：您好，截至2025年12月19日，公司股东户数为34363。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400006460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300485","BK0012","BK0028","BK0046"],"gpt_icon":0},{"id":"2591661157","title":"赛升药业：截至2025年12月10日股东户数为35036","url":"https://stock-news.laohu8.com/highlight/detail?id=2591661157","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591661157?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:45","pubTimestamp":1765788350,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)12月15日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，截止到2025年12月12日公司最近的股东户数是多少，谢谢赛升药业回复：您好，截至2025年12月10日，公司股东户数为35036。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500019024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0012","BK0239","300485"],"gpt_icon":0},{"id":"2588880978","title":"赛升药业（300485）披露子公司收到药品注册上市许可申请受理通知书，12月4日股价下跌0.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588880978","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588880978?lang=zh_cn&edition=full","pubTime":"2025-12-04 22:14","pubTimestamp":1764857665,"startTime":"0","endTime":"0","summary":"截至2025年12月4日收盘，赛升药业报收于11.45元，较前一交易日下跌0.17%，最新总市值为55.15亿元。该股当日开盘11.5元，最高11.56元，最低11.28元，成交额达6186.47万元，换手率为1.98%。公司近日发布公告称，其子公司北京赛而生物药业有限公司收到国家药品监督管理局下发的达格列净二甲双胍缓释片境内生产药品注册上市许可申请的《受理通知书》。药品注册批准时间及结果存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400039534.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300485","BK0012","BK0028","BK0239"],"gpt_icon":0},{"id":"2588011380","title":"赛升药业(300485.SZ)：达格列净二甲双胍缓释片药品注册上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2588011380","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588011380?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:02","pubTimestamp":1764835358,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛升药业(300485.SZ)发布公告，公司子公司北京赛而生物药业有限公司(以下简称“赛而生物”)近日收到了国家药品监督管理局下发的达格列净二甲双胍缓释片境内生产药品注册上市许可申请的《受理通知书》。SGLT-2抑制药达格列净和盐酸二甲双胍的复方片剂由英国阿斯利康制药公司研发，于2014年FDA批准上市。2023年6月，该品种在我国批准上市。SGLT-2 抑制剂是通过非胰岛素依赖机制发挥作用，通过减少葡萄糖在肾脏的重吸，从尿中直接排糖来降低血糖，SGLT-2联用二甲双胍表现了更好的降糖效果和更低的副作用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"赛升药业(300485.SZ)：达格列净二甲双胍缓释片药品注册上市许可申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0046","BK0012","BK0239","300485"],"gpt_icon":0},{"id":"2584099949","title":"赛升药业：11月18日高管马丽减持股份合计6.3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2584099949","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584099949?lang=zh_cn&edition=full","pubTime":"2025-11-19 21:02","pubTimestamp":1763557346,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月19日市场公开信息、上市公司公告及交易所披露数据整理，赛升药业（300485）最新董监高及相关人员股份变动情况：2025年11月18日公司董事,高管马丽共减持公司股份6.3万股，占公司总股本为0.0131%。变动期间公司股价下跌2.94%，11月18日当日收盘报12.86元。赛升药业近半年内的董监高及核心技术人员增减持详情如下：赛升药业的高管列表及最新持股情况如下：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900037687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0012","300485","BK0028"],"gpt_icon":0},{"id":"2584678940","title":"股市必读：赛升药业(300485)股东户数3.56万户，较上期减少4.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584678940","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584678940?lang=zh_cn&edition=full","pubTime":"2025-11-18 01:06","pubTimestamp":1763399182,"startTime":"0","endTime":"0","summary":"截至2025年11月17日收盘，赛升药业报收于13.25元，下跌0.75%，换手率10.52%，成交量28.8万手，成交额3.8亿元。来自股本股东变化：截至11月10日股东户数环比下降4.03%，户均持股上升至1.35万股，筹码集中度提升。股本股东变化股东户数变动近日赛升药业披露，截至2025年11月10日公司股东户数为3.56万户，较10月20日减少1498.0户，减幅为4.03%。户均持股数量由上期的1.3万股增加至1.35万股，户均持股市值为16.53万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800000708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0012","300485","BK0028"],"gpt_icon":0},{"id":"2582813229","title":"股市必读：赛升药业（300485）11月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2582813229","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582813229?lang=zh_cn&edition=full","pubTime":"2025-11-10 03:25","pubTimestamp":1762716314,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，赛升药业报收于11.93元，下跌0.58%，换手率2.82%，成交量7.71万手，成交额9234.95万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000001307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300485","BK0046","BK0239","BK0012"],"gpt_icon":0},{"id":"2581700790","title":"赛升药业最新公告：取得换发《药品生产许可证》","url":"https://stock-news.laohu8.com/highlight/detail?id=2581700790","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581700790?lang=zh_cn&edition=full","pubTime":"2025-11-07 17:12","pubTimestamp":1762506722,"startTime":"0","endTime":"0","summary":"赛升药业(300485.SZ)公告称，近日收到北京市药品监督管理局换发的《药品生产许可证》，换发后的《药品生产许可证》的有效期至2030年11月4日。新生产许可证的取得确保了公司的正常生产经营，不会对公司业绩产生重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700026883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","BK0239","300485","BK0012"],"gpt_icon":0},{"id":"2581154072","title":"赛升药业：公司现任董事长为马骉先生","url":"https://stock-news.laohu8.com/highlight/detail?id=2581154072","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581154072?lang=zh_cn&edition=full","pubTime":"2025-11-07 16:21","pubTimestamp":1762503675,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)11月07日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司现任董事长是谁？赛升药业回复：您好，公司现任董事长为马骉先生。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700024923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0012","300485","BK0028"],"gpt_icon":0},{"id":"2579597197","title":"赛升药业：截至2025年10月20日股东户数为37145","url":"https://stock-news.laohu8.com/highlight/detail?id=2579597197","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579597197?lang=zh_cn&edition=full","pubTime":"2025-10-30 16:57","pubTimestamp":1761814627,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)10月30日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！请问截止10月20号，公司的股东人数是多少？谢谢赛升药业回复：您好，截至2025年10月20日，公司股东户数为37145。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000030854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0239","300485","BK0028","BK0046"],"gpt_icon":0},{"id":"2578712525","title":"赛升药业（300485）2025年三季报简析：净利润同比增长152.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578712525","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578712525?lang=zh_cn&edition=full","pubTime":"2025-10-25 06:09","pubTimestamp":1761343761,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期赛升药业发布2025年三季报。根据财报显示，赛升药业净利润同比增长152.81%。截至本报告期末，公司营业总收入3.09亿元，同比下降4.41%，归母净利润5185.96万元，同比上升152.81%。按单季度数据看，第三季度营业总收入1.12亿元，同比上升3.5%，第三季度归母净利润407.33万元，同比下降41.41%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102500005688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485"],"gpt_icon":0},{"id":"2577046203","title":"赛升药业最新公告：第三季度净利润同比下降41.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577046203","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577046203?lang=zh_cn&edition=full","pubTime":"2025-10-23 20:30","pubTimestamp":1761222607,"startTime":"0","endTime":"0","summary":"赛升药业(300485.SZ)公告称，赛升药业发布2025年第三季度报告，报告显示，公司前三季度实现营业收入3.09亿元，同比下降4.41%，但净利润达到5185.96万元，同比增长152.81%。第三季度单季，公司营业收入为1.12亿元，同比增长3.5%，净利润为407.33万元，同比下降41.41%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300035157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485"],"gpt_icon":0},{"id":"2575479931","title":"赛升药业(300485)9月30日股东户数3.34万户，较上期减少1.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575479931","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575479931?lang=zh_cn&edition=full","pubTime":"2025-10-13 17:10","pubTimestamp":1760346639,"startTime":"0","endTime":"0","summary":"证券之星消息，近日赛升药业披露，截至2025年9月30日公司股东户数为3.34万户，较9月19日减少618.0户，减幅为1.82%。在生物制品行业个股中，赛升药业股东户数低于行业平均水平，截至9月30日，生物制品行业平均股东户数为3.41万户。从股价来看，2025年9月19日至2025年9月30日，赛升药业区间跌幅为5.38%，在此期间股东户数减少618.0户，减幅为1.82%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300019341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300485","BK0012","BK0046","BK0028"],"gpt_icon":0},{"id":"2570098613","title":"赛升药业(300485)9月19日股东户数3.4万户，较上期减少0.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2570098613","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570098613?lang=zh_cn&edition=full","pubTime":"2025-09-25 17:33","pubTimestamp":1758792795,"startTime":"0","endTime":"0","summary":"证券之星消息，近日赛升药业披露，截至2025年9月19日公司股东户数为3.4万户，较9月10日减少270.0户，减幅为0.79%。在生物制品行业个股中，赛升药业股东户数低于行业平均水平，截至9月19日，生物制品行业平均股东户数为3.42万户。从股价来看，2025年9月10日至2025年9月19日，赛升药业区间跌幅为2.19%，在此期间股东户数减少270.0户，减幅为0.79%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092500025666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0028","300485","BK0046"],"gpt_icon":0},{"id":"2569205622","title":"股市必读：赛升药业（300485）9月19日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2569205622","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569205622?lang=zh_cn&edition=full","pubTime":"2025-09-22 02:59","pubTimestamp":1758481148,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘，赛升药业报收于12.08元，下跌0.74%，换手率3.22%，成交量8.81万手，成交额1.06亿元。董秘最新回复投资者： 请问董秘，贵司在研技术和产品，以往都有介绍。当日关注点来自交易信息汇总：9月19日主力资金净流出682.87万元，散户资金净流入1277.87万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092200000979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0012","BK0046","BK0239","300485"],"gpt_icon":0},{"id":"2568502572","title":"赛升药业(300485.SZ)股东马丽和刘淑芹拟合计减持不超2%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2568502572","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568502572?lang=zh_cn&edition=full","pubTime":"2025-09-19 19:54","pubTimestamp":1758282870,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛升药业(300485.SZ)公告，公司股东马丽女士和刘淑芹女士计划在2025年10月21日至2026年1月20日通过集中竞价和大宗交易方式减持公司股份数量合计不超过963.33万股，即不超过公司当前总股本的2%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1347465.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0012","BK0046","300485","BK0239"],"gpt_icon":0},{"id":"2568258490","title":"赛升药业：布局生命科学大健康产业","url":"https://stock-news.laohu8.com/highlight/detail?id=2568258490","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568258490?lang=zh_cn&edition=full","pubTime":"2025-09-19 15:39","pubTimestamp":1758267546,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)09月19日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，贵司在研技术和产品，以往都有介绍。贵司还涉猎生命科学大健康产业，请问有哪些产品或研究成果？赛升药业回复：您好，公司致力于生命科学技术产业化发展，通过自主创新，上、下游产业链整合，资本市场运作等方式布局覆盖生命科学大健康产业相关领域，以往介绍的产品、在研项目等均属于该范畴。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091900019158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485","BK0046","BK0028","BK0239","BK0012"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768326266317,"stockEarnings":[{"period":"1week","weight":0.0906},{"period":"1month","weight":0.1207},{"period":"3month","weight":-0.0098},{"period":"6month","weight":-0.1137},{"period":"1year","weight":0.8286},{"period":"ytd","weight":0.1493}],"compareEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":0.0641},{"period":"3month","weight":0.0579},{"period":"6month","weight":0.1768},{"period":"1year","weight":0.3094},{"period":"ytd","weight":0.0428}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京赛升药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"33621人(较上一季度减少2.16%)","perCapita":"8144股","listingDate":"2015-06-26","address":"北京市大兴区北京经济技术开发区兴盛街8号","registeredCapital":"48166万元","survey":" 北京赛升药业股份有限公司的主营业务是注射针剂的研发、生产及销售。公司的主要产品是免疫系统用药、神经系统用药、心脑血管用药。赛盈®纤溶酶注射液被评选为2023年年度生化生物企业优秀品牌，赛典®单唾液酸四己糖神经节苷脂钠注射液被评为2024年度生化、生物药品优秀品牌。","listedPrice":38.46},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供赛升药业(300485)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"赛升药业,300485,赛升药业股票,赛升药业股票老虎,赛升药业股票老虎国际,赛升药业行情,赛升药业股票行情,赛升药业股价,赛升药业股市,赛升药业股票价格,赛升药业股票交易,赛升药业股票购买,赛升药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供赛升药业(300485)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}